In the News

Houston, Texas (April 15, 2026) – Re:Cognition Health, a global leader in new treatments for Alzheimer’s Disease, is delivering an international clinical trial to evaluate whether a simple finger-prick blood test can revolutionize how Alzheimer’s disease is diagnosed. Compared with the current invasive and expensive diagnostic methods, this approach could provide a scalable solution for […]

Apr 17, 2026 | Dementias & Alzheimer’s, Immunoassay |      The study will analyze three key proteins to determine if blood-based biomarkers can provide an earlier and more accessible diagnostic method. Re:Cognition Health is delivering an international clinical trial to evaluate whether a finger-prick blood test can improve how Alzheimer’s disease is diagnosed. Compared with current invasive and expensive diagnostic methods, this approach aims […]

Siemens Healthineers has become a licensed partner in the Bio-Hermes-002 Alzheimer’s study. Erin Brady April 13, 2026 The Global Alzheimer’s Platform Foundation (GAP) has announced that Siemens Healthineers has joined the Bio-Hermes-002 study alongside several other industry leaders. Siemens is now a licensed partner of the study, aiming to enhance Alzheimer’s diagnostics. Specifically, Siemens Healthineers will work to “change the paradigm […]

The Global Alzheimer’s Platform Foundation (GAP) has announced a strategic collaboration with Siemens Healthineers for the Bio-Hermes-002 study, an observational platform designed to evaluate biomarkers for Alzheimer’s disease and related dementias. The study compares blood-based and digital biomarkers across a wide range of cognitive conditions, alongside MRI and PET imaging data, to generate insights that […]

Siemens Healthineers joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias  Washington D.C., Apr. 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare, to the Bio-Hermes-002 study. This collaboration will enhance this unique, […]

Tampa, FL, Mar 25, 2026—  Axiom Brain Health (Axiom) is pleased to announce Dr. Susan Steen will be honored by the Alzheimer’s Association – Florida Gulf Coast Chapter at the Inspire, Imagine, and Hope Gala on Friday, March 27, 2026, at The Gathering @ Armature Works in Tampa. “I am delighted to receive this honor from the […]

By Knowridge -March 25, 2026Alzheimer’s disease is one of the most common causes of memory loss in older adults. It slowly affects the brain, making it harder for people to remember things, think clearly, and carry out daily activities. As the global population ages, more and more families are facing the challenges of this condition. Because of […]

Alzheimer’s disease is one of the most feared illnesses of aging. It slowly damages memory, thinking, and behavior, and over time it makes it difficult for people to carry out everyday tasks. For decades, scientists have focused mainly on one key feature of the disease: sticky clumps of a protein called amyloid that build up […]

The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas WASHINGTON, DC (Feb. 27, 2026) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2025 National Citizen Scientist Awards® elevated honorees. GAP’s Citizen Scientist Awards (CSA) acknowledge the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases.  This year’s award […]

Long before Alzheimer’s disease became a global crisis, it was already shaping quiet, devastating stories inside individual families. Science was fragmented. Treatments were elusive. And for decades, progress moved more slowly than anyone anticipated. For entrepreneurs working in healthcare, the challenge was not just scientific. It was structural. How do you build companies that can […]

Las Vegas is set to host a significant gathering of Alzheimer’s and Parkinson’s disease research leaders this week, as the Global Alzheimer’s Platform Foundation (GAP) convenes its annual conference from February 25th through February 27th at the Red Rock Casino Resort & Spa. The event will bring together nearly 250 representatives from over 100 clinical […]

by Chloe KoastTue, February 24, 2026 at 9:36 AM From February 25th through the 27th the Global Alzheimer’s Platform Foundation will meet up at the Red Rock Casino Resort & Spa. More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer’s. This includes announcing a new […]

Researchers and Executives from almost 50 clinical trial sites, pharmaceutical companies and technology partners to collaborate on improving research & treatment options Las Vegas., Feb. 20, 2026- From February 25 through February 27 the Global Alzheimer’s Platform Foundation® (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s and neurodegenerative clinical trials in pursuit of a cure, will convene nearly 250 representatives from […]

The disease currently is diagnosed using expensive scans and lumbar punctures or spinal taps. February 18, 2026 By: Michael Barbella Managing Editor Alzheimer’s disease detection could be quite literally at our fingertips. A major international research project is underway at the U.K. Dementia Research Institute (DRI) to test whether a finger prick-style blood test could be […]

Diagnosing the disease can be expensive, invasive and complicated. Research in RI could help speed up the process Feb. 5, 2026, 5:04 a.m. ETEAST PROVIDENCE – Alzheimer’s, a neurodegenerative disease, is the primary cause of dementia in the United States. In Rhode Island, more than one in 10 adults over age 65 – about 22,000 […]

This Nature article highlights how blood-based biomarkers for Alzheimer’s disease stand to have the potential to transform diagnostics, and how new treatments and therapies are developed. There is mention of how Bio-Hermes-001, and Bio-Hermes-002, use head-to-head comparisons of blood-based biomarkers and digital tests to explore which combinations of blood-based biomarkers perform best across different populations and […]

“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact.  A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with […]

“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin […]

Tori Rodriguez, MA, LPC, AHC Publish DateJanuary 27, 202 At the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held December 1 to 4, 2025, in San Diego, California, researchers presented new data spanning observational studies, biomarker analyses, and clinical development programs in Alzheimer disease (AD). Key topics included emerging evidence on metabolic therapies such as […]

Alzheimer’s disease study brings new testing to Las Vegas Courtesy Axiom Brain Health’s Kaden Appleberry processes lab sample for study. By Katie Ann McCarver (contact) Monday, January 26, 2026 – 2 a.m. A Las Vegas stronghold in neurology is contributing to a new study spanning multiple states and countries related to the detection and diagnosis of Alzheimer’s disease. Clinical Neurology […]

by News 3 Staff,Updated Fri, January 23, 2026 at 1:20 PM LAS VEGAS (KSNV) — Clinical Neurology Specialists (CNS) in Las Vegas is participating in a groundbreaking international study sponsored by the Global Alzheimer’s Platform Foundation. The Bio-Hermes-002 study seeks volunteers with memory concerns to help identify blood or digital tests that could predict the presence of amyloid […]

Jan 20, 2026 | staff reporterSave for later NEW YORK — UK nonprofit research organization LifeArc said on Monday that it has partnered with the Global Alzheimer’s Platform Foundation (GAP) to evaluate a blood-based test for Alzheimer’s disease. The test is designed to detect three proteins — phosphorylated tau 217, glial fibrillary acidic protein, and neurofilament light […]

Washington D.C., Jan 20, 2026, The Global Alzheimer’s Platform Foundation® (GAP) applauds the House and Senate Committees on appropriations releasing their final bipartisan FY2026 Labor–Health and Human Services–Education appropriations bill which increases funding for Alzheimer’s disease and other dementia research.     “Congress’s bipartisan approval of increased funding for neurodegenerative research sends a powerful message to the millions of […]

The test aims to pick up three proteins known to be associated with Alzheimer’s Jane KirbyMonday 19 January 2026 11:14 GMT Bookmark popover Removed from bookmarksClose popover A pioneering trial has begun to assess whether a simple finger-prick blood test could offer an early diagnosis for Alzheimer’s disease, even before symptoms manifest. Experts are optimistic […]